Galderma Raises 2026 Sales Guidance on Strong Growth
By Sarah Sloat
Swiss skincare company Galderma raised its sales outlook for the year after sales grew strongly in the first half.
In the first six months, net sales rose 25% to $3.13 billion at constant currencies, with growth driven predominantly by volume and complemented by favorable mix, it said. Galderma now expects net sales growth between 19% and 21% at constant currencies, up from a forecast of 17%-20% previously.
The company's core earnings before interest, taxes, depreciation and amortization in the first half rose to $802 million from $555 million, while the core Ebitda margin was 25.6% compared with 22.7% in the same period a year earlier.
Galderma confirmed its margin expectation for 2026, with a core Ebitda margin of approximately 26% at constant currencies.
Write to Sarah Sloat at sarah.sloat@wsj.com
(END) Dow Jones Newswires
July 23, 2026 02:56 ET (06:56 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
